HPV and cervical cancer in Moldova – cost/benefit mode
Închide
Articolul precedent
Articolul urmator
556 4
Ultima descărcare din IBN:
2021-04-07 11:12
SM ISO690:2012
JARYNOWSKI, Andrzej. HPV and cervical cancer in Moldova – cost/benefit mode. In: Tendinţe contemporane ale dezvoltării ştiinţei: viziuni ale tinerilor cercetători, Ed. 4, 10 martie 2015, Chișinău. Chișinău, Republica Moldova: Universitatea Academiei de Ştiinţe a Moldovei, 2015, Ediția 4, T, p. 149.
EXPORT metadate:
Google Scholar
Crossref
CERIF

DataCite
Dublin Core
Tendinţe contemporane ale dezvoltării ştiinţei: viziuni ale tinerilor cercetători
Ediția 4, T, 2015
Conferința "Tendinţe contemporane ale dezvoltării ştiinţei: viziuni ale tinerilor cercetători"
4, Chișinău, Moldova, 10 martie 2015

HPV and cervical cancer in Moldova – cost/benefit mode


Pag. 149-149

Jarynowski Andrzej12
 
1 Universitatea de Stat din Moldova,
2 Universitatea Jagiellonă din Cracovia
 
 
Disponibil în IBN: 18 februarie 2019



Teza

Human papillomavirus, or HPV, is a sexually transmittable virus infection, which is necessary risk factor for developing cervical cancer - first most common type of cancer in working age women in Moldova. We observe both behavioral change (sexuality increase) and demographical change (population ageing). The main goal is the authoritative analysis of the costs and losses of potential epidemiological control strategies and identifies potential problems that health care will have to face in the future. We run computer simulation to prepare cost/benefit analyze for different vaccination strategies, various screening programs and preventive programs (using condoms) for Moldova, based on its own demography and sexual behavior. We used data since 1998 to adjust model parameter and we project till 2031. We use mathematical and sociological concepts within complex system methodology. Moldovan cervical cancer perspective looks much better, than in central/western Europe countries, because of relatively young society. In our setup, obligatory vaccination seems to not be so crucial (for none of realistic scenarios increase of cancer cases is possible) for public health, as in most countries in European Union. However, screening practice could be verified in terms of efficiency, when cost/benefit calculation would be done. We propose more optimal screening guidelines, which could provide saving perspective in 10-15 year in range 100-300k EUR yearly. Targeted vaccination could be also consider, because costs are similar to high frequencies screening schema with the same cancer cases projection. However, some positive side effects of vaccination as reduction of pathogen circulation in society, will cause decrease of other pathologies related to HPV like genital warts and other cancer.